APOP Stock Doubles on Solid Outcome of ApoGraft

APOP stock

APOP stock is having a solid day with a gain of over 100% after Cellect Biotechnology Ltd. (NASDAQ:APOP) reported positive results from its ongoing Phase 1/2 clinical study of ApoGraft.

Solid News

One stock that has gone on an impressive rally this morning is Israel-based biotechnology company Cellect Biotechnology. It has emerged that the Data and Safety Monitoring Board (DSMB) has completed a review of Cellect’s product ApoGraft and made its recommendations. The review was done during the Phase 1 and Phase 2 studies of the product that are currently ongoing, and in its review, the ...

Read The Full Article On MicroSmallCap.com

Get early insight on hidden secret gems on MicroSmallCap. Follow Crypto, Mining, Cannabis and Energy stocks and get free research reports here.

All content provided by MicroSmallCap is subject to our Terms Of Use and Disclaimer.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.